Common Terminology Criteria for Adverse Events (CTCAE) is widely accepted as the standard classification and severity grading scale for adverse events in cancer therapy, clinical trials and other oncology settings. Version 5.0 is the most updated document (November 27, 2017)
A study, published recently in Clinical Lymphoma, Myeloma and Leukemia, has further validated the use of the SKY92 gene expression signature as a potentially valuable prognostic tool to evaluate myeloma patients. Compared with seven other gene expression profiling classifiers including UAMS 70, UAMS 80 and IFM15, the researchers found that SKY92 identified the largest proportion (21%)…
Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Heaney JLJ et al. Br J Haematol. 2017 Jun 1. doi: 10.1111/bjh.14753. [Epub ahead of print]. Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease. Hofmann JN et al. Obesity (Silver Spring). 2017 Jun 11. doi: 10.1002/oby.21894. [Epub ahead of print]. Diffusion-weighted whole-body MRI for…
